NanoDimension

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. tHEY were founded on breakthrough computationally-designed virus-like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington.

Natron Energy, Inc. is an energy storage company based in Santa Clara, California, specializing in the development of sodium ion battery technologies for industrial applications. Founded in 2012, the company designs batteries that feature high power, long cycle life, and affordability, utilizing a unique Prussian blue chemistry. Natron Energy's products are suitable for various stationary applications, including uninterruptible power supplies, lift trucks, renewable energy smoothing, smart grids, and regulatory compliance. Additionally, the company operates a software-defined power platform that enhances its energy storage solutions, making them adaptable for critical backup power systems and electric vehicle fast charging, among other uses. Previously known as Alveo Energy, Natron Energy rebranded in March 2017 to better reflect its focus on innovative energy storage solutions.

SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.

Arctos Medical is a spin-off company from the University of Bern and has developed a revolutionary gene therapy that does not correct rare genetic eye diseases but much more common cases of blindness.

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. tHEY were founded on breakthrough computationally-designed virus-like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington.

Amphivena Therapeutics is a clinical-stage immuno-oncology company focused on developing bifunctional antibody therapies aimed at treating hematologic malignancies. Founded in 2012 and based in South San Francisco, California, the company utilizes its proprietary ReSTORE platform to create dual-action biologics that enhance the patient's immune response against cancer. These therapies are designed to relieve immune suppression while activating T cells, thereby promoting the destruction of tumor cells and their precursors. The platform emphasizes avidity, target selectivity, and safety, and can be engineered to include additional functionalities for targeting solid tumors. As a subsidiary of Affimed N.V., Amphivena Therapeutics aims to provide innovative treatment options for patients facing blood cancers.

Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.

Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.

SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.

Serotiny, Inc. is a biotechnology company based in San Francisco, California, that specializes in the design and development of multi-domain proteins and therapies aimed at treating cancers and genetic disorders. Founded in 2014, Serotiny utilizes a combination of mammalian synthetic biology and informatics to achieve rational protein design. The company collaborates with leaders in the life sciences to create innovative therapies and tools, tailoring its protein designs to meet specific therapeutic needs.

Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.

H55 S.A. manufactures electric propulsion system and battery management solutions for aircrafts. It offers software and hardware solutions for integrating propeller, transmission systems, electric motors and controllers, energy storage, and pilot interface. The company was founded in 2015 and is based in Sion, Switzerland.

ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.

Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.

Tarveda Therapeutics, Inc. develops cancer therapies that address the challenges of treating solid tumors. It offers Pentarin, a miniature drug conjugate medicine for the treatment of patients with solid tumor malignancies. Tarveda Therapeutics, Inc. was formerly known as Blend Therapeutics, Inc. and changed its name to Tarveda Therapeutics, Inc. in January 2016. The company was founded in 2011 and is based in Watertown, Massachusetts.

Emulate, Inc. specializes in organs-on-chips technology designed to mimic human biology, enabling a better understanding of how diseases, medications, chemicals, and food impact human health. The company offers organ-chips that replicate the functions and disease states of various human organs, including the lung, intestine, liver, and skin. In addition to its organ-chips, Emulate provides software applications for drug development and research workflows, catering to a diverse clientele that includes biotechnology and pharmaceutical companies, consumer health and cosmetics industries, agricultural firms, and academic researchers. Founded in 2013 and based in Boston, Massachusetts, Emulate aims to set a new standard for accurately predicting human responses across multiple fields, including drug development and personalized medicine. The company was previously known as Emulate Living MicroDevices, Inc. before rebranding in 2014.

SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.

ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.

As of January 8, 2019, Pulse Therapeutics, Inc. was acquired by Ichor Vascular, Inc. Pulse Therapeutics, Inc., a medical technology company, develops magnetically-enhanced diffusion (MED) system for the treatment of stroke, heart, and other diseases. Its MED system is used to harness magnet-based technology to dissolve blood clots faster than current modalities. The company also provides MED MicroBeads that are designed to convey physician-selected agents faster to the blood clot; intravenously administered after thrombolysis therapy is initiated; and mechanical adjunct to standard of care IV thrombolysis. In addition, it offers touch screen operated MED Workstation. Pulse Therapeutics, Inc. was incorporated in 2008 and is based in St. Louis, Missouri.

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.

Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.

Crocus Technology International Corp. specializes in developing and supplying magnetic sensors and embedded memory solutions based on its patented magnetic logic unit technology. The company provides a range of magnetic sensor products, which include various architectures suitable for challenging environments, such as oil drilling, fluid level measurements, and solar energy applications. Its offerings cater to diverse sectors, including industrial, automotive, consumer electronics, and the Internet of Things. Additionally, Crocus Technology delivers magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries, addressing needs in telecommunications, networking, storage, computing, and handheld devices. Established in 2014, the company is headquartered in Santa Clara, California, with an additional office in Grenoble, France, and distributes its products through a network of sales distributors both domestically and internationally.

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.

Tarveda Therapeutics, Inc. develops cancer therapies that address the challenges of treating solid tumors. It offers Pentarin, a miniature drug conjugate medicine for the treatment of patients with solid tumor malignancies. Tarveda Therapeutics, Inc. was formerly known as Blend Therapeutics, Inc. and changed its name to Tarveda Therapeutics, Inc. in January 2016. The company was founded in 2011 and is based in Watertown, Massachusetts.

Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.

Emulate, Inc. specializes in organs-on-chips technology designed to mimic human biology, enabling a better understanding of how diseases, medications, chemicals, and food impact human health. The company offers organ-chips that replicate the functions and disease states of various human organs, including the lung, intestine, liver, and skin. In addition to its organ-chips, Emulate provides software applications for drug development and research workflows, catering to a diverse clientele that includes biotechnology and pharmaceutical companies, consumer health and cosmetics industries, agricultural firms, and academic researchers. Founded in 2013 and based in Boston, Massachusetts, Emulate aims to set a new standard for accurately predicting human responses across multiple fields, including drug development and personalized medicine. The company was previously known as Emulate Living MicroDevices, Inc. before rebranding in 2014.

ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.

Tarveda Therapeutics, Inc. develops cancer therapies that address the challenges of treating solid tumors. It offers Pentarin, a miniature drug conjugate medicine for the treatment of patients with solid tumor malignancies. Tarveda Therapeutics, Inc. was formerly known as Blend Therapeutics, Inc. and changed its name to Tarveda Therapeutics, Inc. in January 2016. The company was founded in 2011 and is based in Watertown, Massachusetts.

View, Inc. specializes in designing and manufacturing glass systems for various sectors, including workplace, healthcare, education, and hospitality. Founded in 2006 and headquartered in Milpitas, California, with manufacturing facilities in Olive Branch, Mississippi, the company focuses on enhancing natural light in buildings through its innovative smart window technology. View's products, known for their energy efficiency and positive impact on human health and productivity, utilize artificial intelligence to automatically adjust to sunlight, optimizing light access while minimizing energy consumption. The company markets its solutions through direct sales and representatives both domestically and internationally, positioning itself as a leader in the smart windows industry.

Crocus Technology International Corp. specializes in developing and supplying magnetic sensors and embedded memory solutions based on its patented magnetic logic unit technology. The company provides a range of magnetic sensor products, which include various architectures suitable for challenging environments, such as oil drilling, fluid level measurements, and solar energy applications. Its offerings cater to diverse sectors, including industrial, automotive, consumer electronics, and the Internet of Things. Additionally, Crocus Technology delivers magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries, addressing needs in telecommunications, networking, storage, computing, and handheld devices. Established in 2014, the company is headquartered in Santa Clara, California, with an additional office in Grenoble, France, and distributes its products through a network of sales distributors both domestically and internationally.

View, Inc. specializes in designing and manufacturing glass systems for various sectors, including workplace, healthcare, education, and hospitality. Founded in 2006 and headquartered in Milpitas, California, with manufacturing facilities in Olive Branch, Mississippi, the company focuses on enhancing natural light in buildings through its innovative smart window technology. View's products, known for their energy efficiency and positive impact on human health and productivity, utilize artificial intelligence to automatically adjust to sunlight, optimizing light access while minimizing energy consumption. The company markets its solutions through direct sales and representatives both domestically and internationally, positioning itself as a leader in the smart windows industry.

Tarveda Therapeutics, Inc. develops cancer therapies that address the challenges of treating solid tumors. It offers Pentarin, a miniature drug conjugate medicine for the treatment of patients with solid tumor malignancies. Tarveda Therapeutics, Inc. was formerly known as Blend Therapeutics, Inc. and changed its name to Tarveda Therapeutics, Inc. in January 2016. The company was founded in 2011 and is based in Watertown, Massachusetts.

View, Inc. specializes in designing and manufacturing glass systems for various sectors, including workplace, healthcare, education, and hospitality. Founded in 2006 and headquartered in Milpitas, California, with manufacturing facilities in Olive Branch, Mississippi, the company focuses on enhancing natural light in buildings through its innovative smart window technology. View's products, known for their energy efficiency and positive impact on human health and productivity, utilize artificial intelligence to automatically adjust to sunlight, optimizing light access while minimizing energy consumption. The company markets its solutions through direct sales and representatives both domestically and internationally, positioning itself as a leader in the smart windows industry.

They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.

Crocus Technology International Corp. specializes in developing and supplying magnetic sensors and embedded memory solutions based on its patented magnetic logic unit technology. The company provides a range of magnetic sensor products, which include various architectures suitable for challenging environments, such as oil drilling, fluid level measurements, and solar energy applications. Its offerings cater to diverse sectors, including industrial, automotive, consumer electronics, and the Internet of Things. Additionally, Crocus Technology delivers magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries, addressing needs in telecommunications, networking, storage, computing, and handheld devices. Established in 2014, the company is headquartered in Santa Clara, California, with an additional office in Grenoble, France, and distributes its products through a network of sales distributors both domestically and internationally.

Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.

SBA Materials, Inc. engages in the development and commercialization of advanced electronic materials for back-end of line and packaging applications for semiconductor manufacturing. The company focuses on commercializing low-k dielectric materials for interlayer dielectric application to address the needs of the semiconductor manufacturing industry. Its products include uLK22, uLK1X, and optical films, as well as nano-porous/meso-porous materials. The company offers materials to address the unmet needs of electronic device manufacturers. SBA Materials, Inc. was founded in 2001 and is based in Albuquerque, New Mexico.

Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.

Crocus Technology International Corp. specializes in developing and supplying magnetic sensors and embedded memory solutions based on its patented magnetic logic unit technology. The company provides a range of magnetic sensor products, which include various architectures suitable for challenging environments, such as oil drilling, fluid level measurements, and solar energy applications. Its offerings cater to diverse sectors, including industrial, automotive, consumer electronics, and the Internet of Things. Additionally, Crocus Technology delivers magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries, addressing needs in telecommunications, networking, storage, computing, and handheld devices. Established in 2014, the company is headquartered in Santa Clara, California, with an additional office in Grenoble, France, and distributes its products through a network of sales distributors both domestically and internationally.

Xtellus, Inc. provides reconfigurable optical add/drop multiplexers (ROADM) technology and dynamic optical modules for agile optical networking systems. It offers wavelength selective switches, wavelength blockers, edge wavelength selective switches, and ROADM modules with integrated power monitoring and muxes/demuxes; and liquid crystal optical processors. Xtellus, Inc. was founded in 2000 and is based in Morris Plains, New Jersey. It has manufacturing and development facilities in Israel and South Korea. The company also has a research and development facility in Jerusalem, Israel. As of December 17, 2009, Xtellus, Inc. operates as a subsidiary of Oclaro, Inc.

They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.